P M Hooymans
Overview
Explore the profile of P M Hooymans including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
48
Citations
290
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Gilissen L, Derijks L, Bos L, Bus P, Hooymans P, Engels L
Clin Drug Investig
. 2007 May;
24(8):479-86.
PMID: 17523708
Background And Objective: Azathioprine is widely used in the treatment of corticosteroid-dependent and refractory inflammatory bowel disease (IBD). The efficacy of this treatment is based on the production of 6-thioguanine...
12.
Ausems M, Hulsewe K, Hooymans P, Hoofwijk A
Anaesthesia
. 2007 Mar;
62(4):325-31.
PMID: 17381566
The aim of this study was to evaluate our postoperative pain protocol after ambulatory herniorrhaphy and to determine how infiltration with local anaesthetics would add to our management of postoperative...
13.
De Boer N, Derijks L, Keizer-Garritsen J, Lambooy L, Ruitenbeek W, Hooymans P, et al.
J Clin Pharmacol
. 2007 Jan;
47(2):187-91.
PMID: 17244769
The proposed metabolic advantage of 6-thioguanine (6-TG) is the direct conversion into the pharmacologically active 6-thioguaninenucleotides (6-TGN). The authors assessed metabolic characteristics of 6-TG treatment in patients with Crohn's disease...
14.
Gilissen L, Derijks L, Driessen A, Bos L, Hooymans P, Stockbrugger R, et al.
Dig Liver Dis
. 2006 Dec;
39(2):156-9.
PMID: 17188950
Background: 6-Thioguanine is used in inflammatory bowel disease since 2001, with promising short-term results. In 2003, liver histology of some 6-thioguanine treated patients showed nodular regenerative hyperplasia. Recently, magnetic resonance...
15.
Derijks L, Gilissen L, Hooymans P, Hommes D
Aliment Pharmacol Ther
. 2006 Aug;
24(5):715-29.
PMID: 16918876
Background: In the past 10-20 years, knowledge of both thiopurine pharmacology and -pharmacogenetics has been extended dramatically and used to develop new strategies to improve efficacy and reduce toxicity. Aim:...
16.
Gilissen L, Derijks L, Verhoeven H, Bierau J, Hooymans P, Hommes D, et al.
Dig Liver Dis
. 2006 Aug;
39(2):182-6.
PMID: 16880012
In a 23-year-old female with colonic Crohn's disease 6-mercaptopurine 100 mg daily (1.7 mg/kg) was added to mesalamine and prednisolone therapy because of ongoing disease activity. One month later she...
17.
Gilissen L, Bierau J, Derijks L, Bos L, Hooymans P, van Gennip A, et al.
Aliment Pharmacol Ther
. 2005 Sep;
22(7):605-11.
PMID: 16181300
Background: In vitro studies suggest interactions between mesalazine (mesalamine) and thiopurines by thiopurine S-methyltransferase (TPMT) inhibition, influencing the balance of hepatotoxic 6-methylmercaptopurine ribonucleotide and immunosuppressive tioguanine (thioguanine) metabolites. Aim: To...
18.
de Jong D, Derijks L, Naber A, Hooymans P, Mulder C
Scand J Gastroenterol Suppl
. 2004 Jan;
(239):69-72.
PMID: 14743886
Background: Thiopurines have proven efficacy in inflammatory bowel disease. However, concerns regarding toxicity have limited the use of these agents as first line of medical therapy. Methods: Review of the...
19.
Merkus F, Lohman J, ter Berg J, Hooymans P
Cephalalgia
. 2002 Sep;
22(7):513-9.
PMID: 12230592
Drugs which directly counteract nitric oxide (NO), such as endothelial receptor blockers, NO-synthase inhibitors, and NO-scavengers, may be effective in the acute treatment of migraine, but are also likely to...
20.
van der Kuy P, Lohman J, Hooymans P, ter Berg J, Merkus F
Eur J Clin Pharmacol
. 2000 Jan;
55(9):677-80.
PMID: 10638398
Objective: A comparison of the pharmacokinetic properties of two novel intranasal preparations of dihydroergotamine mesilate (DHEM) with a commercially available intranasal preparation. Methods: Two intranasal formulations of DHEM in combination...